NYSE · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · SMALL CAP
Volitionrx Ltd. VNRX
15 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 1.7M
Revenue, FY2025 · full 15-year series below
Revenue $M
Net income $M
FY2025 · Revenue 1.7 · Net income -23.4
Compound annual growth
Revenue compounded at +164.1% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−1361 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -1258.5% · Net -1360.6%
ROE
FY2022 · ROE -404.0%
The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | 0.0 | · | 0.0 | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | · | · | · | · | · | · | · | · | · | · | −0.0 | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | · | −0.31 | −0.50 | · | −0.51 | −0.45 | −0.41 | −0.57 | −0.56 | −0.52 | −0.54 | −0.61 | −0.34 | −0.44 | −0.45 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | −404.0 | −158.7 | −133.8 | −122.2 | −163.0 | −94.9 | −87.5 | −297.2 | −1566.2 | −490.0 | −424.7 | −239.5 |
| Shares out B | 0.13 | 0.10 | 0.08 | 0.06 | 0.05 | 0.05 | 0.04 | 0.04 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 57 reconciliationsAUDITED
Reconciled in 15 of 19 fiscal years. 19 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityIn Vitro & In Vivo Diagnostic Substances
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011